WIXOM, Mich., June 10, 2008 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a specialty pharma company focused on drug and device development in the renal market, reported today that it has added Dr. Richard Zager, an expert in acute renal injury and renal failure to its Scientific Advisory Board (SAB). Rockwell’s SAB currently advises the Company on clinical development and market preparation for its proprietary iron-maintenance product SFP, currently in Phase IIb clinical trials. Rockwell’s SAB consists of experts in the fields of renal anemia, iron therapy, nephrology and FDA regulatory approval.
